RUSH UNIVERSITY MEDICAL CENTER

Arthrex®

For more information on the trial please visit: *www.ACPClinicalTrial.com*

IDE- FL1-00025-EN_B

ARTHREX ACP® AUTOLOGOUS CONDITIONED PLASMA INTRA-ARTICULAR (IA) INJECTIONS FOR KNEE OSTEOARTHRITIS (OA) CLINICAL TRIAL

Dr. Cole, Dr. Yanke and Dr. Weber

are currently enrolling patients in the Arthrex ACP® Autologous Conditioned Plasma Clinical Trial at

Midwest Orthopaedics at Rush.

The purpose of this clinical trial is to evaluate the effectiveness of ACP IA injections using Arthrex's ACP Double Syringe System compared to Normal Saline IA injections. This treatment was designed to investigate the safety and effectiveness of ACP in treating pain in subjects with primary OA of the knee. The Arthrex ACP system allows rapid and efficient concentration of platelets and growth factors from autologous blood for use at the treatment site. If successful, possible benefits may include significant decrease in knee pain, improvement in knee function and range of motion.

Participants in the trial are randomized to receive either the ACP treatment or the Normal Saline in a 2:1 ratio. The study will follow participants for 12 months post treatment to assess functional outcomes, need for treatment revisions and adverse events.

Basic Inclusion Criteria:

- Between the ages of 18 and 70
- Has diagnosis of knee osteoarthritis

REFER A PATIENT!

For more information or to refer a patient for enrollment in this trial, contact:

Kavita Ahuja

kavita.ahuja@rushortho.com

(312) 912-4701

Rush University Medical Center

Chicago, IL, United States, 60612

Further information regarding this trial can be found at www.clinicaltrials.gov and www.ACPclinicaltrial.com